170 related articles for article (PubMed ID: 33564303)
21. Overexpression of long non-coding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer.
Sun W; Lan X; Wang Z; Dong W; He L; Zhang T; Zhang H
Med Oncol; 2016 Sep; 33(9):102. PubMed ID: 27510368
[TBL] [Abstract][Full Text] [Related]
22. MiR-202-3p functions as a tumor suppressor and reduces cell migration and invasion in papillary thyroid carcinoma.
Chen J; Yin J; Liu J; Zhu RX; Zheng Y; Wang XL
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1145-1150. PubMed ID: 30779083
[TBL] [Abstract][Full Text] [Related]
23. LncRNA GAS8-AS1 inhibits cell proliferation through ATG5-mediated autophagy in papillary thyroid cancer.
Qin Y; Sun W; Zhang H; Zhang P; Wang Z; Dong W; He L; Zhang T; Shao L; Zhang W; Wu C
Endocrine; 2018 Mar; 59(3):555-564. PubMed ID: 29327301
[TBL] [Abstract][Full Text] [Related]
24. LRP4 promotes proliferation, migration, and invasion in papillary thyroid cancer.
Zhou X; Xia E; Bhandari A; Zheng C; Xiang J; Guan Y; Zhang X
Biochem Biophys Res Commun; 2018 Sep; 503(1):257-263. PubMed ID: 29885843
[TBL] [Abstract][Full Text] [Related]
25. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
Pang R; Yang S
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
[TBL] [Abstract][Full Text] [Related]
26. LDOC1 is differentially expressed in thyroid cancer and display tumor-suppressive function in papillary thyroid carcinoma.
Zhao S; Zhao Y; Wang Q; Li Z; Ma X; Wu L; Li W; Du M; Ji H; Qin G
Cell Biol Int; 2020 Apr; 44(4):985-997. PubMed ID: 31889386
[TBL] [Abstract][Full Text] [Related]
27. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
28. ZCCHC12, a novel oncogene in papillary thyroid cancer.
Wang O; Zheng Z; Wang Q; Jin Y; Jin W; Wang Y; Chen E; Zhang X
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1679-1686. PubMed ID: 28424903
[TBL] [Abstract][Full Text] [Related]
29. MiR-145 functions as a tumor suppressor in Papillary Thyroid Cancer by inhibiting RAB5C.
Zhang W; Ji W; Li T; Liu T; Zhao X
Int J Med Sci; 2020; 17(13):1992-2001. PubMed ID: 32788878
[TBL] [Abstract][Full Text] [Related]
30. Expression of ANGPTL2 and its impact on papillary thyroid cancer.
Yang L; Sun R; Wang Y; Fu Y; Zhang Y; Zheng Z; Ji Z; Zhao D
Cancer Cell Int; 2019; 19():204. PubMed ID: 31384179
[TBL] [Abstract][Full Text] [Related]
31. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
32. MiR-577 inhibits papillary thyroid carcinoma cell proliferation, migration and invasion by targeting SphK2.
Xue KC; Hu DD; Zhao L; Li N; Shen HY
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3794-3800. PubMed ID: 28975989
[TBL] [Abstract][Full Text] [Related]
33. LINC00641 impeded the malignant biological behaviors of papillary thyroid carcinoma cells via interacting with IGF2BP1 to reduce GLI1 mRNA stability.
Meng D; Zhao S; Wu L; Ma X; Zhao D; Li Z
Hum Exp Toxicol; 2023; 42():9603271231180856. PubMed ID: 37291850
[TBL] [Abstract][Full Text] [Related]
34. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
[TBL] [Abstract][Full Text] [Related]
35. JAZF1 Suppresses Papillary Thyroid Carcinoma Cell Proliferation and Facilitates Apoptosis via Regulating TAK1/NF-κB Pathways.
Huang L; Cai Y; Luo Y; Xiong D; Hou Z; Lv J; Zeng F; Yang Y; Cheng X
Onco Targets Ther; 2019; 12():10501-10514. PubMed ID: 31819531
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-150 targets Rho-associated protein kinase 1 to inhibit cell proliferation, migration and invasion in papillary thyroid carcinoma.
Cheng L; Zhou R; Chen M; Feng L; Li H
Mol Med Rep; 2017 Aug; 16(2):2217-2224. PubMed ID: 28656254
[TBL] [Abstract][Full Text] [Related]
37. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
38. Tripartite Motif Containing 3 inhibits the aggressive behaviors of papillary thyroid carcinoma and indicates lower recurrence risk.
Song Y; Gao Z; Yan Z; Zheng C
Genes Genomics; 2022 Apr; 44(4):455-465. PubMed ID: 34860317
[TBL] [Abstract][Full Text] [Related]
39. PDZK1 Interacting Protein 1 Promotes the Progression of Papillary Thyroid Cancer.
Wang K; Liu S; Tian Y; Liu C; Gui Z; Yu T; Zhang L
J Clin Endocrinol Metab; 2022 Aug; 107(9):2449-2461. PubMed ID: 35727731
[TBL] [Abstract][Full Text] [Related]
40. Semaphorin 3D inhibits proliferation and migration of papillary thyroid carcinoma by regulating MAPK/ERK signaling pathway.
Hai R; You Q; Wu F; Qiu G; Yang Q; Shu L; Xie L; Zhou X
Mol Biol Rep; 2022 May; 49(5):3793-3802. PubMed ID: 35190928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
